Navigation Links
Altogen Labs Announces Patent Filing for Bioremediation Process and Oil Spill Cleanup Products
Date:10/26/2012

AUSTIN, Texas, Oct. 26, 2012 /PRNewswire/ -- Altogen Labs announced the filing of a patent for bioremediation microorganism isolation and selection methods (USPTO application 13/490,508). This environmental technology is based on isolation of naturally present microorganisms in heavily contaminated soil, which allows accelerating natural bioremediation processes. We don't have to wait hundreds of years for nature to degrade an oil spill or clean up land contaminated with toxic chemicals and carcinogens. Instead, by reintroducing natural bacteria to oil spill sites, Altogen Labs accomplish oil degradation process in just a few months. This bioaugmentation platform technology to remediate crude oil and chemical spills can be applied worldwide.

Both laboratory and field tests showed that Altogen Labs site-specific bacterial strains are highly effective for remediation of crude oil- and petroleum-saturated earth. The bacteria is grown in the lab to speed up the natural process and then re-introduced to the contaminated site. Multiple lab studies show that after consuming the oil and having no remaining food source, the bacteria die. No adverse effects of using the live bacteria have been observed, and the effectiveness and safety of the method are remarkable. Scientists at Altogen Labs used functional genomics to perform whole genome sequencing study to characterize these newly identified natural microorganisms and identify specific biosurfactant and quorum-sensing genes that allow the microorganisms to work together for efficient and effective crude oil spill bioremediation.

Altogen Labs also offers soil remediation services and development programs focused on other chemical contaminations besides crude oil, including remediation of soil with recalcitrant organic chemical spills including polycyclic aromatic hydrocarbons, petroleum, pesticides, herbicides, perchlorate, carbon tetrachloride, chloroform, acetone, benzene, toluene, xylenes, perchloroethylene, chlorofluorocarbon, aliphatic chlorinated hydrocarbons, and other industrial and chemical manufacturing wastes and spills.

Altogen Labs announced that site-specific bioremediation products will be manufactured and sold through its exclusive distributor - Soil Bioremediation Inc (www.soil-bio-remediation.com) located in Austin, Texas.

About Altogen Labs

Altogen Labs (www.altogenlabs.com) is GLP compliant laboratory that provides biotechnology research services and biology CRO services to pharmaceutical, biotechnology, and academic institutions worldwide. Bioremediation is one of the company's focus areas. This bioaugmentation-based soil remediation technology provides conversion of toxic, environment-contaminating compounds into innocuous substances by using natural oil-degrading bacteria.

Contact
Altogen Labs
4020 South Industrial Dr, Suite 130
Austin TX 78744 USA
(512) 433-6177
Web: www.altogenlabs.com
E-mail: info@altogenlabs.com


'/>"/>
SOURCE Altogen Labs
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... New FDA action date of July 22, 2016 ... 22, 2016   --> - New ... - Lifitegrast has the potential to be the only product ... signs and symptoms of dry eye disease in adults --> ... in the U.S. in the past decade indicated for the treatment of signs ...
(Date:2/4/2016)... , Feb. 4, 2016 Beike Biotechnology, the ... medical institutions attended a ceremony in late 2015 to ... cell therapy in 2016. --> ... Translation Platform for Personalized Cell Therapy" was hosted by ... Production Center, both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... , Feb. 4, 2016 ContraVir Pharmaceuticals, Inc. ... the development and commercialization of targeted antiviral therapies, announced ... Investor Conference 2016, to be held February 8-9, 2016, ... Group,s 2016 Disruptive Growth & Healthcare Conference, taking place ... 10-11, 2016. James Sapirstein , Chief Executive ...
(Date:2/4/2016)... 4, 2016 Strasbourg, France ... --> Strasbourg, France , to the ... PharmaVentures is pleased to announce that it acted as an ... unit in Strasbourg, France , to the ... --> --> Transgene (Euronext: TNG), a member ...
Breaking Biology Technology:
(Date:2/3/2016)... DUBLIN , Feb. 3, 2016 /PRNewswire/ ... announced the addition of the "Emotion ... NLP, Machine Learning, and Others), Software Tools ... Application Areas, End Users,and Regions - Global ... offering. --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) ...
(Date:2/2/2016)... 2016 This BCC Research report provides ... reviewing the recent advances in high throughput ‘omic ... field forward. Includes forecast through 2019. ... and opportunities that exist in the bioinformatic market. ... as well as IT and bioinformatics service providers. ...
(Date:2/2/2016)... 2016 Technology Enhancements Accelerate Growth of X-ray Imaging ... digital and computed radiography markets in Thailand ... Indonesia (TIM). It provides an in-depth ... well as regional market drivers and restraints. The study ... and market attractiveness, both for digital and computed radiography. ...
Breaking Biology News(10 mins):